Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

12-Week study shows benvitimod cream is efficacious and safe in plaque psoriasis

Jan. 21, 2021

Arcutis plans to study roflumilast foam in phase III for seborrheic dermatitis

Jan. 21, 2021

Positive confirmatory data from atopic dermatitis cohort of EDP-1815 phase Ib trial

Jan. 21, 2021

Arcutis initiates pivotal phase III studies of roflumilast cream in patients with atopic dermatitis

Jan. 14, 2021

Dovobet Foam approved in Japan for psoriasis

Jan. 13, 2021

Cara opens phase II trial of oral difelikefalin for notalgia paresthetica pruritus

Jan. 11, 2021

New phase II trial evaluates SCD-044 for moderate to severe plaque psoriasis

Jan. 5, 2021

New CTP synthase 1 inhibitors described by Step Pharma

Dec. 29, 2020

New acetyl-CoA carboxylase inhibitors discovered at Almirall

Dec. 29, 2020

Topline data from pivotal phase II/III VALO study of Qtorin rapamycin in pachyonychia congenita

Dec. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...